

## Special Issue

# Clinical Diagnosis, Treatment, and Prognosis of Uveal Melanoma

### Message from the Guest Editor

Uveal melanoma (UM) is a rare intraocular cancer with an incidence of 4.2 cases per million each year. It is the most common primary intraocular malignancy in adults and the second most common form of melanoma after melanoma of the skin. Patients are usually treated with globe-conserving methods such as radiotherapy or surgical resections, but in the case of large tumors, enucleation is required. Tebentafusp, recently approved for the systemic treatment of metastatic lesions, has raised hope for these patients. Minimally invasive methods, such as tumoral biopsies and recently liquid biopsies, would be extremely beneficial, allowing clinical and molecular prognostication, with the aim of early detection of metastases to increase the likelihood of adequate treatment to improve the survival of these patients. In this Special Issue, experts in this field will review the current approaches to the diagnosis, management and prognosis of patients affected by UM.

---

### Guest Editor

Dr. Josep Maria Caminal Mitjana

Department of Ophthalmology, Ocular Oncology and Vitreoretinal Service, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain

---

### Deadline for manuscript submissions

30 June 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/188722](https://mdpi.com/si/188722)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)